Stelar’s New Solution for Advanced Tumor Tissue Characterization
Discover also Relax4Ti project!
Welcome to the Future of Tumor Analysis
Stelar proudly unveils a groundbreaking innovation for cancer research and pre-clinical analysis:
Fast Field Cycling (FFC) NMR Relaxometer for Tumor Tissue Characterization.
Leveraging our cutting-edge expertise in Fast Field Cycling (FFC) NMR Relaxometry technology, we offer a novel solution for a fast and simple characterization of tumor tissues, providing unprecedented insights into cancer treatment efficacy.
The Challenge: Improving Tumor Response Monitoring in Cancer Treatment
Accurate tumor characterization is essential for understanding tumor gradiation and aggressiveness, optimizing treatment effectiveness. However, traditional imaging techniques and other analysis methods often fail to detect subtle changes within tumor tissues, leading to delays in adjusting treatment strategies. This lack of sensitivity can result in less timely and effective interventions, hindering optimal patient outcomes.
By improving monitoring techniques, we can enable earlier and higher-sensitivity treatment adjustments, ultimately enhancing the effectiveness of cancer therapies.
The Solution: Fast Field-Cycling Nuclear Magnetic Resonance (FFC) NMR Relaxometry
Fast Field Cycling (FFC) NMR Relaxometry offers a cutting-edge, non-invasive approach to timely measure a critical biomarker, linked to tumor structure, cell density, and treatment responsiveness.
About the FFC Instrument
Benchtop: Small footprint
Software: Research based, easy to apply
Key benefits of our advanced FFC NMR system include:
-
- Accurate measurement of intracellular water lifetime enables real-time monitoring of tumor tissue changes.
- Early detection of treatment efficacy, allowing clinicians to make timely adjustments for optimized therapy.
- High sensitivity to microstructural tissue changes, often identifying alterations before they become visible through conventional imaging techniques.
This innovative technology provides valuable insights into tumor dynamics, empowering more informed and effective clinical decision-making.
Why Choose Stelar’s FFC NMR for Tumor Tissue Characterization?
-
- Unparalleled Sensitivity: Detect intracellular water lifetime changes with unmatched precision.
- Early Detection: Identify treatment efficacy before morphological changes are visible.
- Non-Invasive: A non-destructive technique that preserves tissue integrity.
- Validated by Science: Backed by leading research institutions, including the University of Torino, and recognized in key publications.
Who Can Benefit?
This application is perfectly suited for:
-
- Cancer Research Institutes: Conduct advanced pre-clinical studies on tumor tissues to enhance understanding and treatment strategies.
- Hospitals: Monitor patient responses to treatment through non-invasive methods, enabling real-time adjustments to care plans.
- Oncology Labs: Discover new insights into tumor microstructure and progression, facilitating innovative research and breakthroughs in cancer therapy.
Unlock New Possibilities in Cancer Research
-
- Empower your research and clinical teams with Stelar’s FFC NMR Relaxometry—the premier solution for tumor tissue characterization.
- Elevate your cancer research with rapid, precise insights into treatment efficacy, paving the way for innovative breakthroughs and improved patient outcomes.
Science-Driven Innovation
Powered by Stelar’s state-of-the-art hardware and validated through rigorous research at the University of Torino, our solution offers a groundbreaking approach to monitoring tumor microstructure across diverse cancer models. This advancement unlocks new possibilities in cancer treatment and preclinical research analysis.
References:
•Ruggiero, M. R., Baroni, S., Bitonto, V., Ruiu, R., Rapisarda, S., Aime, S., & Crich, S. G. Intracellular Water Lifetime as a Tumor Biomarker to Monitor Doxorubicin Treatment via FFC-Relaxometry in a Breast Cancer Model. Frontiers in Oncology, 11. https://doi.org/10.3389/FONC.2021.778823
•In Vivo Breast Cancer Study: Baroni, S., Ruggiero, M. R., Bitonto, V., Broche, L. M., Lurie, D. J., Aime, S., & Crich, S. G. (2020). In vivo assessment of tumour associated macrophages in murine melanoma obtained by low-field relaxometry in the presence of iron oxide particles. Biomaterials, 236, 119805.
•Baroni, Simona, et al. “Exploring the tumour extracellular matrix by in vivo Fast Field Cycling relaxometry after the administration of a Gadolinium‐based MRI contrast agent.” Magnetic Resonance in Chemistry 57.10 (2019): 845-851.
• M. Pasin, G. Ferrante (Stelar Srl), S.Geninatti Crich (Dep. of Molecular Biotechnology and Health Sciences, University of Torino) – Case Study: In Vivo Tumor Characterization – FFC application notes: in vivo © 2019 Stelar srl _ AN 191001_in vivo
GET IN TOUCH!
Discover how Stelar’s FFC NMR system can transform your research and elevate your results.